WallStreetZenWallStreetZen

NASDAQ: GTHX
G1 Therapeutics Inc Stock Ownership - Who owns G1 Therapeutics?

Insider buying vs selling

Have G1 Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Monica R. ThomasChief Legal People Officer2024-05-235,826$4.27
$24.87kSell
John W. V. UmsteadChief Financial Officer2024-05-138,151$4.79
$39.04kSell
Rajesh MalikChief Medical Officer2024-05-138,151$4.79
$39.04kSell
Mark AvaglianoChief Business Officer2024-05-138,151$4.79
$39.04kSell
John E. Jack Bailey Jr.President and CEO2024-05-1337,258$4.79
$178.43kSell
Andrew PerryChief Commercial Officer2024-05-138,151$4.79
$39.04kSell
Terry L. MurdockChief Operating Officer2024-05-138,151$4.79
$39.04kSell
John W. V. UmsteadChief Financial Officer2024-03-186,547$3.02
$19.75kSell
Rajesh MalikChief Medical Officer2024-02-1228,600$4.62
$132.13kSell
Rajesh MalikChief Medical Officer2024-02-1228,600$0.30
$8.58kBuy

1 of 4

GTHX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GTHX insiders and whales buy or sell their stock.

GTHX Shareholders

What type of owners hold G1 Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Clay Thorp14.18%7,411,440$22.16MInsider
Ra Capital Management LP9.50%4,968,488$14.86MInsider
Fredric N. Eshelman7.06%3,689,151$11.03MInsider
Eshelman Ventures LLC6.58%3,439,151$10.28MInsider
Medimmune Ventures Inc5.64%2,950,630$8.82MInsider
Vanguard Group Inc3.98%2,081,573$6.22MInstitution
Susquehanna International Group LLP1.82%950,839$2.84MInstitution
Renaissance Technologies LLC1.73%903,700$2.70MInstitution
Raymond James Associates1.54%802,835$2.40MInstitution
D E Shaw Co Inc1.50%785,259$2.35MInstitution

1 of 3

GTHX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GTHX27.36%46.96%Net SellingNet Selling
BOLD65.21%23.96%Net BuyingNet Buying
CNTX5.25%1.54%
KOD68.53%31.47%Net SellingNet Selling
PRQR20.64%0.00%

G1 Therapeutics Stock Ownership FAQ

Who owns G1 Therapeutics?

G1 Therapeutics (NASDAQ: GTHX) is owned by 27.36% institutional shareholders, 46.96% G1 Therapeutics insiders, and 25.68% retail investors. Clay Thorp is the largest individual G1 Therapeutics shareholder, owning 7.41M shares representing 14.18% of the company. Clay Thorp's G1 Therapeutics shares are currently valued at $20.60M.

If you're new to stock investing, here's how to buy G1 Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.